Literature DB >> 27605068

Specific immunotherapy in ovarian cancer: a systematic review.

Soroush Aalipour1, Samaneh Zoghi1, Nastaran Khalili1, Armin Hirbod-Mobarakeh1,2,3, Leisha A Emens4, Nima Rezaei2,3,5.   

Abstract

Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. Several approaches of active and passive immunotherapy for EOC have been studied. The aim of this systematic review was to assess the clinical efficacy of specific immunotherapy in patients with EOC. We found 4524 references in seven databases and we included ten controlled clinical trials with 2285 patients with EOC reporting five active immunotherapeutic agents and three passive immunotherapies. Meta-analysis of six studies showed that overall there was not any significant difference in overall survival and recurrence-free survival between patients undergoing specific immunotherapy and those in control group. Most of the studies we evaluated reported a positive outcome from treatment with specific immunotherapy, although this was not significant.

Entities:  

Keywords:  active immunotherapy; clinical outcome; immunotherapy; meta-analysis; ovarian cancer; passive immunotherapy; systematic review; vaccines

Mesh：

Year:  2016        PMID： 27605068     DOI： 10.2217/imt-2016-0034

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


  16 in total

1.  p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.

Authors:  Nicola R Hardwick; Paul Frankel; Christopher Ruel; Julie Kilpatrick; Weimin Tsai; Ferdynand Kos; Teodora Kaltcheva; Lucille Leong; Robert Morgan; Vincent Chung; Raechelle Tinsley; Melissa Eng; Sharon Wilczynski; Joshua D I Ellenhorn; Don J Diamond; Mihaela Cristea
Journal:  Clin Cancer Res       Date:  2018-01-04       Impact factor: 12.531

2.  Neoantigens from the bench to the bedside: new prospective for ovarian cancer immunotherapy.

Authors:  Chiara Napoletano; Filippo Bellati
Journal:  Ann Transl Med       Date:  2019-12

3.  Nitidine chloride inhibited the expression of S phase kinase-associated protein 2 in ovarian cancer cells.

Authors:  Huaping Mou; Ping Guo; Xiaoming Li; Chuanli Zhang; Jing Jiang; Lishuai Wang; Qiu Wang; Zhiping Yuan
Journal:  Cell Cycle       Date:  2017-06-08       Impact factor: 4.534

4.  DFMO and 5-Azacytidine Increase M1 Macrophages in the Tumor Microenvironment of Murine Ovarian Cancer.

Authors:  Meghan Travers; Stephen M Brown; Matthew Dunworth; Cassandra E Holbert; Karla R Wiehagen; Kurtis E Bachman; Jackson R Foley; Meredith L Stone; Stephen B Baylin; Robert A Casero; Cynthia A Zahnow
Journal:  Cancer Res       Date:  2019-05-14       Impact factor: 12.701

Review 5.  Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.

Authors:  Anne M Macpherson; Simon C Barry; Carmela Ricciardelli; Martin K Oehler
Journal:  J Clin Med       Date:  2020-09-14       Impact factor: 4.241

6.  Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma.

Authors:  Malgorzata Czystowska-Kuzmicz; Anna Sosnowska; Dominika Nowis; Kavita Ramji; Marta Szajnik; Justyna Chlebowska-Tuz; Ewa Wolinska; Pawel Gaj; Magdalena Grazul; Zofia Pilch; Abdessamad Zerrouqi; Agnieszka Graczyk-Jarzynka; Karolina Soroczynska; Szczepan Cierniak; Robert Koktysz; Esther Elishaev; Slawomir Gruca; Artur Stefanowicz; Roman Blaszczyk; Bartlomiej Borek; Anna Gzik; Theresa Whiteside; Jakub Golab
Journal:  Nat Commun       Date:  2019-07-05       Impact factor: 14.919

7.  Extracellular vesicles released by ovarian carcinoma contain arginase 1 that mitigates antitumor immune response.

Authors:  Anna Sosnowska; Malgorzata Czystowska-Kuzmicz; Jakub Golab
Journal:  Oncoimmunology       Date:  2019-08-20       Impact factor: 8.110

Review 8.  Advances in ovarian cancer therapy.

Authors:  Alexander J Cortez; Patrycja Tudrej; Katarzyna A Kujawa; Katarzyna M Lisowska
Journal:  Cancer Chemother Pharmacol       Date:  2017-12-16       Impact factor: 3.333

9.  Overexpression of kinesin family member 20A is associated with unfavorable clinical outcome and tumor progression in epithelial ovarian cancer.

Authors:  Han Li; Weijing Zhang; Xiaoying Sun; Jueming Chen; Yue Li; Chunhao Niu; Benke Xu; Yanna Zhang
Journal:  Cancer Manag Res       Date:  2018-09-12       Impact factor: 3.989

10.  Identification of differentially expressed genes and signaling pathways in ovarian cancer by integrated bioinformatics analysis.

Authors:  Xiao Yang; Shaoming Zhu; Li Li; Li Zhang; Shu Xian; Yanqing Wang; Yanxiang Cheng
Journal:  Onco Targets Ther       Date:  2018-03-15       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.